ArticleBMC cancer2025
Single-cell perspective on the Monocyte-to-HDL cholesterol ratio as a metastasis biomarker in papillary thyroid cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Serum 25(OH)D and HDL-C as site-specific metabolic markers of cervical lymph node metastasis in papillary thyroid carcinoma.World journal of surgical oncology · 2026Article
- PKM2-Mediated Glycolytic Reprogramming in Thyroid Cancer: Mechanistic Insights and Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Declined RTN3 stabilizes DHCR7 to induce cholesterol-dependent tumor progression and MEK inhibitors insensitivity in thyroid cancer.Cell death & disease · 2026Article
- Integrative multi-omics and machine learning framework identifies PRDX4 as a redox-EMT regulator and predictive marker in bone-metastatic breast cancer.NPJ precision oncology · 2026Article
- CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPapillary thyroid carcinoma (PTC) is a globally widespread inflammation-related cancer, where lymph node metastasis (LNM) poses significant challenges to the prognosis of PTC. The role of the monocyte-to-high-density lipoprotein cholesterol ratio (MHR), a novel inflammation marker attracting increasing attention, in PTC remains unclear.
methodsClinical data analysis was adopted to preliminarily explore the relationship between clinical features and LNM of PTC. Single-cell RNA sequencing (scRNA-seq) data from the GSE191288 and GSE193581 datasets were integrated to analyze various single-cell infiltration in PTC. A comprehensive suite of in vitro experiments, encompassing immunohistochemistry, co-culture, and Transwell assays were conducted to elucidate the regulatory role of macrophages and PTC.
resultsClinical data analysis confirmed MHR could be an independent risk factor for LNM (OR = 1.76, 95%CI: 1.20-2.88, P = 0.011). The single-cell analysis identified cell clusters associated with dysregulated cholesterol homeostasis Q1 and CD68 + C3 macrophage subpopulations, as well as their markers GDF15. Further analysis confirmed that they are closely related to PTC metastasis and malignancy, which also implied a significant correlation between MHR and LNM. The in vitro experiments demonstrated PTC may promote metastasis by mediating inducing macrophage differentiation to the M2 phenotype.
conclusionThis study revealed the potential role of MHR in PTC from the single-cell perspective for the first time. Combined with the results of clinical studies and basic experiments, it was confirmed that mononuclear/macrophage and cholesterol homeostasis significantly promoted the lymph node metastasis of PTC. Overall, these findings informed robust support for MHR as an emerging marker for preoperative LNM prediction of PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.